Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Receivables (2016 - 2025)

Historic Receivables for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $12.1 million.

  • Harvard Bioscience's Receivables fell 562.7% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 562.7%. This contributed to the annual value of $14.9 million for FY2024, which is 765.89% down from last year.
  • As of Q3 2025, Harvard Bioscience's Receivables stood at $12.1 million, which was down 562.7% from $11.9 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Receivables ranged from a high of $21.8 million in Q4 2021 and a low of $11.9 million during Q2 2025
  • In the last 5 years, Harvard Bioscience's Receivables had a median value of $16.1 million in 2023 and averaged $16.0 million.
  • Its Receivables has fluctuated over the past 5 years, first surged by 3214.21% in 2021, then tumbled by 2613.15% in 2024.
  • Harvard Bioscience's Receivables (Quarter) stood at $21.8 million in 2021, then decreased by 23.49% to $16.7 million in 2022, then dropped by 3.63% to $16.1 million in 2023, then decreased by 7.66% to $14.9 million in 2024, then dropped by 18.55% to $12.1 million in 2025.
  • Its Receivables was $12.1 million in Q3 2025, compared to $11.9 million in Q2 2025 and $13.5 million in Q1 2025.